A novel drug for patients with brain cancer, 2B3-101, has shown preliminary positive results. The Dutch biotech to-BBB has developed 2B3-101 and initiated a clinical trial to investigate this new treatment. The Phase I safety results will be presented at the European Cancer Congress 2013 in Amsterdam at the end of September.
29 September, 2013
Who decides which diseases to treat?
17 September, 2013
Zealand Pharma has announced an exclusive peptide drug research and development collaboration agreement with Eli Lilly and Company (“Lilly”).
10 September, 2013
Complex human brain tissue has been successfully developed in a three-dimensional culture system established in an Austrian laboratory.
06 September, 2013
Researchers at the University of Leuven (KU Leuven) are joining forces with Janssen Pharmaceuticals Inc. (Janssen) and the Wellcome Trust to discover and develop candidate antiviral drugs for the prevention and treatment of dengue infection.
03 September, 2013